FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains

The Food and Drug Administration (FDA) expanded the support of Moderna’s RSV vaccine precocious Thursday to see individuals 18-59 years of property who are astatine accrued hazard for terrible unwellness from respiratory syncytial virus, the institution said.  The vaccine was antecedently lone licensed for adults aged 60 years and older.  “RSV poses a superior health…